8/21/2013

Selexys Pharmaceuticals has started patient enrollment for a midstage study of the experimental sickle cell disease drug SelG1. The trial, which will involve about 175 patients, will evaluate the drug's safety and efficacy with the goal of decreasing the frequency of sickle cell-related pain crises.

Related Summaries